Cytokeratin 18 Antibody (B-6): sc-398871

Cytokeratin 18 Antibody (B-6) is a mouse monoclonal IgG1 antibody that detects Cytokeratin 18 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Cytokeratin 18 is a vital component of the cytoskeleton in epithelial cells, contributing significantly to structural integrity and resilience. Cytokeratin 18 is predominantly located in the cytoplasm, forming a network of intermediate filaments that provide mechanical support and shape to cells. Proper localization of Cytokeratin 18 is crucial for maintaining epithelial tissue architecture, and disruption can lead to various pathological conditions, including cancer. Cytokeratin 18 serves as a biomarker for epithelial-derived tumors, as expression levels can indicate differentiation status of malignant cells. Post-translational modifications of Cytokeratin 18, such as phosphorylation, can influence protein interactions and overall cellular function. Anti-Cytokeratin 18 antibody (B-6) serves as an essential tool for researchers studying epithelial biology and cancer pathology, providing insights into Cytokeratin 18′s role in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 18 Antibody (B-6) References:

1. Cytokeratin 18 expression in immature Sertoli cells: co-localization with interstitial lymphocytic infiltrates.  |  Kruse, R., et al. 2009. Folia Histochem Cytobiol. 47: 127-30. PMID: 19419951
2. Cytokeratin 18 expression inhibits cytokine-induced death of cervical cancer cells.  |  Sullivan, BT., et al. 2010. Int J Gynecol Cancer. 20: 1474-81. PMID: 21119362
3. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.  |  Lebensztejn, DM., et al. 2011. Acta Biochim Pol. 58: 563-6. PMID: 22140659
4. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments.  |  Kwok, R., et al. 2014. Aliment Pharmacol Ther. 39: 254-69. PMID: 24308774
5. Increased expression levels of E-cadherin, cytokeratin 18 and 19 observed in preeclampsia were not correlated with disease severity.  |  Li, XL., et al. 2014. Placenta. 35: 625-31. PMID: 24857367
6. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis.  |  Rosso, C., et al. 2016. Dig Liver Dis. 48: 55-61. PMID: 26514735
7. High serum levels of caspase-cleaved cytokeratin-18 are associated with malignant middle cerebral artery infarction patient mortality.  |  Lorente, L., et al. 2018. BMC Neurol. 18: 32. PMID: 29573748
8. Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.  |  Kovac, RL., et al. 2018. J Vet Intern Med. 32: 2061-2068. PMID: 30353992
9. Elevated Serum Level of Cytokeratin 18 M65ED Is an Independent Indicator of Cardiometabolic Disorders.  |  Qian, L., et al. 2020. J Diabetes Res. 2020: 5198359. PMID: 32337295
10. The adenovirus L3 23-kilodalton proteinase cleaves the amino-terminal head domain from cytokeratin 18 and disrupts the cytokeratin network of HeLa cells.  |  Chen, PH., et al. 1993. J Virol. 67: 3507-14. PMID: 7684469

The preferred Cytokeratin 18 antibody is Cytokeratin 18 Antibody (RGE53): sc-32329.